OLMA olema.com: Enterprise Value-to-Revenue Ratio

Public company logo of Olema Pharmaceuticals, Inc. (OLMA)

The development of potent molecules to block estrogen receptors relies on the professionalism of the management team, which is successfully conducting final drug tests for Olema Pharmaceuticals (OLMA). The company's valuation via EV/Sales demonstrates the result of this synergy, where the value 0.00 captures the metric level. Such dynamics confirm the status of a biopharmaceutical leader investing in the creation of high-precision oral inhibitors for women's oncology therapy.

Olema Pharmaceuticals (OLMA): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Olema Pharma (OLMA)

- price and consensus price forecast:
- company stock capitalization data:
Initial company analysis:Olema Pharmaceuticals
Mass-produced product of Olema Pharmaceuticals, Inc.

The operational revenue dynamics of Olema Pharmaceuticals (OLMA) are directly reflected in the movement of the EV/Revenue multiple. This metric compares the total enterprise value, adjusted for net debt, against the company's annual turnover. Such an approach allows for the assessment of the market value of assets regardless of the debt load. For a biotech firm with a Bayer partnership and a transparent pipeline, this indicator reveals a price imbalance. The analysis helps determine the efficiency of capital management during the clinical trial stage.